Recombinant human granulocyte/macrophage colony-stimulating factor (Harbin Pharmaceutical Group Bioengineering)

注射用重组人粒细胞巨噬细胞刺激因子(哈药集团生物工程有限公司)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant human granulocyte/macrophage colony-stimulating factor (Harbin Pharmaceutical Group Bioengineering)
Drug Alias NameLi Ya Er里亚尔
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionGranulocyte-macrophage colony-stimulating factor receptor modulators
TargetsGranulocyte-macrophage colony-stimulating factor receptor
Therapy Area/IndicationsLeukopeniaMyelodysplastic Syndromes
Global Approved IndicationsLeukopeniaMyelodysplastic Syndromes
Approved Indications in ChinaLeukopeniaMyelodysplastic Syndromes
Original Approved Country/TerritoryMainland China
Original Approved Date1999/01/01
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesHarbin Pharmaceutical Group Holding Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHarbin Pharmaceutical Group Biological Engineering Co Ltd
Inactive CompaniesN/A
Active IndicationsLeukopeniaMyelodysplastic Syndromes
Inactive IndicationsN/A

Other Information

ATC CodeL03AA02
Related LinksN/A